Anfulike

Anfulike is a liposomal formulation of the antifungal agent **amphotericin B**, developed by **CSPC NBP Pharmaceutical**. It was granted drug registration approval in China in March 2021 with priority review. The drug is indicated for the treatment of patients with **invasive fungal infections**, particularly those with renal impairment or drug toxicity that precludes the use of standard amphotericin B deoxycholate, or patients who have failed prior treatment. Its mechanism of action involves binding to **ergosterol** in fungal cell membranes, which leads to the formation of pores that disrupt membrane integrity and cause cell death. By utilizing a liposomal/cholesteryl sulfate complex delivery system, Anfulike alters the metabolism and distribution of amphotericin B, significantly reducing the incidence of nephrotoxicity and hypokalemia compared to conventional formulations.

Brand names

Anfulike

Other names

amphotericin B liposomeliposomal amphotericin Bamphotericin B cholesteryl sulfate complex